NCT05582109View on ClinicalTrials.gov

Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 30, 2022

Primary Completion Date

October 30, 2023

Study Completion Date

October 30, 2025

Conditions
Objective Response Rate (ORR)
Interventions
DRUG

Envafolimab, Lenvatinib Combined With TACE

PD-L1 inhibitor

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT05582109 - Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter